Emergent BioSolutions to develop vaccines with Valneva's cell line

Lyon (France), March 7, 2014 – European biotechnology company Valneva SE (Valneva) announced today that it has signed a new research license agreement and transferred an existing commercial agreement to Emergent BioSolutions Inc. (NYSE:EBS), to develop new vaccines using Valneva’s EB66® cell line.

PDF Download

Source: Valneva

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Valneva

Published: March 7, 2014, 10:40 p.m.

Last updated: March 7, 2014, 11:44 p.m.

Print Share